Skip to main content
Shedir Pharma Group logo

Shedir Pharma Group — Investor Relations & Filings

Ticker · SHE ISIN · IT0005379620 LEI · 81560092B300849E9017 XMIL Manufacturing
Open in API
Filings indexed 124 across all filing types
Latest filing 2024-04-29 AGM Information
Country IT Italy
Listing XMIL SHE

About Shedir Pharma Group

https://www.shedirpharmagroup.com

Shedir Pharma Group specializes in the research, development, formulation, and commercialization of health and wellness products. The company's portfolio encompasses nutraceuticals, dermocosmetics, medical devices, and pharmaceuticals. A key focus is on innovation, resulting in the creation of unique and patented product formulations that cover approximately 15 therapeutic areas. The group operates through specialized subsidiaries that manage the entire product lifecycle, from initial research and intellectual property to marketing and distribution. Products are offered in various forms, such as capsules, tablets, powders, liquids, and gels, targeting professionals in the medical and pharmaceutical sectors.

Recent filings

Filing Released Lang Actions
Assemblea ordinaria degli Azionisti del 29 aprile 2024
AGM Information Classification · 99% confidence The document is a press release (COMUNICATO STAMPA) detailing the outcomes of the Ordinary Shareholders' Meeting (Assemblea ordinaria degli Azionisti) held on April 29, 2024. The key agenda items discussed and approved were the 2023 Financial Statements, the appointment of the Board of Statutory Auditors (Collegio Sindacale), and the engagement of the external auditor (Pricewaterhousecoopers S.p.A.) for the next three years. Since the document reports the results and decisions made during a general meeting of shareholders, it strongly aligns with the purpose of an AGM-related filing, specifically reporting the outcomes of the meeting. While it contains financial results (ER/IR elements), the primary context is the shareholder meeting's resolutions. Therefore, AGM-R (AGM Information) is the most appropriate classification.
2024-04-29 Italian
Comunicato deposito lista collegio sindacale
Governance Information Classification · 98% confidence The document is an official press release ('COMUNICATO STAMPA') from Shedir Pharma Group S.p.A. The subject ('Oggetto') is 'Comunicato deposito lista collegio sindacale' (Communication of filing of the list for the board of statutory auditors). The text explicitly details the list of candidates proposed for the renewal of the 'collegio sindacale' (statutory audit board) ahead of an upcoming Shareholders' Meeting ('Assemblea Ordinaria'). This content relates directly to the governance structure and the process for appointing oversight bodies, which falls under Governance Information (CGR). While it involves an upcoming meeting (related to AGM/DEF 14A), the core subject is the filing/submission of the governance slate itself, making CGR the most precise fit over general meeting materials or remuneration reports.
2024-04-24 Italian
Pubblicazione avviso di convocazione Assemblea ordinaria degli Azionisti
AGM Information Classification · 99% confidence The document is an official announcement titled "Pubblicazione dell'Avviso di Convocazione dell'Assemblea Ordinaria degli Azionisti" (Publication of the Notice of Convocation of the Ordinary Shareholders' Meeting). It details the date, time, location (including provisions for virtual attendance), and the specific agenda items for an upcoming Ordinary Shareholders' Meeting (Assemblea Ordinaria degli Azionisti). The agenda includes approval of the 2023 financial statements, appointment of the statutory auditors, and engagement of the external auditor. This content directly relates to the formal procedures and materials distributed for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2024-04-12 Italian
Deposito della Relazione Finanziaria Annuale 2023 e della documentazione assembleare
Report Publication Announcement Classification · 98% confidence The document is a formal communication from Shedir Pharma Group S.p.A. titled "Deposito della Relazione Finanziaria Annuale 2023 e della documentazione assembleare" (Filing of the 2023 Annual Financial Report and assembly documentation). It explicitly states that the annual financial statements (bilancio di esercizio e bilancio consolidato al 31 dicembre 2023), management report, and related audit/governance documents are being made available to the public, along with assembly documentation (proxy/voting materials). Crucially, the document itself is an announcement *about* the filing and availability of these reports, rather than the full Annual Report (10-K) or the Interim Report (IR) itself. The text states the documents are "messa a disposizione del pubblico" (made available to the public) and directs readers to the website or Borsa Italiana. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. While it mentions the Annual Financial Report (which would typically lead to a 10-K classification if the full report text were present), the nature of this specific filing is the *announcement* of its availability, making RPA the most accurate classification based on the 'MENU VS MEAL' rule.
2024-04-12 Italian
SHEDIR PHARMA BILANCIO 2023 - RICAVI (+10,3%) ED EBITDA (+9,6%) RISPETTO AL 2022
Earnings Release Classification · 99% confidence The document text explicitly states it is a 'COMUNICATO STAMPA' (Press Release) announcing the approval of the draft financial statements ('progetto di bilancio d'esercizio al 31 Dicembre 2023 e il bilancio consolidato al 31 Dicembre 2023'). It provides key financial highlights (Revenues, EBITDA, Net Income) for the year ended December 31, 2023, comparing them to 2022. This structure—a press release summarizing key figures for a full fiscal year—is characteristic of an Earnings Release (ER). Although it contains detailed financial data, the primary format is a communication announcing the results, not the comprehensive, regulated Annual Report (10-K) itself, nor is it a comprehensive Interim Report (IR) as it covers the full year. The mention of approving the financial statements suggests the formal filing (like a 10-K) will follow, making this the initial announcement. FY 2023
2024-03-29 Italian
SHEDIR PHARMA GROUP - CALENDARIO EVENTI SOCIETARI 2024
Regulatory Filings Classification · 99% confidence The document is a formal announcement from Shedir Pharma Group S.p.A. titled 'Shedir Pharma Group S.p.A.: Calendario eventi societari per l'anno 2024' (Shedir Pharma Group S.p.A.: Calendar of corporate events for the year 2024). It explicitly lists future dates for key corporate activities, such as the Board meeting for the approval of the Annual Financial Statements (Bilancio di esercizio) and the Shareholders' Meeting. This type of forward-looking schedule announcement, especially when released outside of a major report filing period, is best classified as a general regulatory announcement or a specific event calendar release. Since there is no specific code for a 'Corporate Calendar Announcement', and it is not a full report (like 10-K or IR), nor a specific announcement like dividend (DIV) or management change (MANG), it falls under the general regulatory filing category, RNS, as it is a mandatory disclosure under Euronext Growth Milan rules (Informazione Regolamentata). The document length is moderate (5759 chars), but its primary function is to communicate the schedule, not to contain the detailed financial data itself.
2024-01-29 Italian

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.